DNA methylation profiling of breast cancer cell lines along the epithelial mesenchymal spectrum - implications for the choice of circulating tumour DNA methylation markers

Anh Viet-Phuong Le, Marcin Szaumkessel, Tuan Zea Tan, Jean Paul Thiery, Erik W. Thompson, Alexander DobrovicbioRxiv 2017 · DOI

TL;DR

This study investigates DNA methylation patterns in breast cancer cell lines that represent different stages of the epithelial-mesenchymal transition (EMT). By profiling methylation across a spectrum of cell lines, the researchers identified distinct methylation signatures associated with epithelial and mesenchymal states, which could be crucial for developing more accurate circulating tumor DNA (ctDNA) methylation markers for cancer monitoring.

What Problem Does This Paper Address?

Breast cancer metastasis is often driven by a process called epithelial-mesenchymal plasticity (EMP), where cancer cells can switch between epithelial and mesenchymal characteristics. This plasticity makes it challenging to identify reliable biomarkers for monitoring cancer, especially using circulating tumor DNA (ctDNA) in blood. Current ctDNA methylation markers may not fully capture the heterogeneity of tumor cells across the EMT spectrum. This paper aims to understand how DNA methylation differs between epithelial and mesenchymal breast cancer cells to identify optimal methylation markers for blood-based cancer monitoring that account for this plasticity.

Methods

The researchers employed Methylation-Sensitive High-Resolution Melting (MS-HRM) to analyze the promoter methylation status of a panel of genes in breast cancer cell lines. MS-HRM is a technique that amplifies specific DNA regions and then analyzes their melting behavior to detect methylation. To validate their findings and quantify methylation levels more precisely, they also used bisulfite pyrosequencing. The study involved a comprehensive panel of 26 breast cancer cell lines that were carefully selected to represent a spectrum from highly epithelial to highly mesenchymal phenotypes.

Datasets

The study utilized a panel of 26 breast cancer cell lines. These cell lines were characterized and ranked along the epithelial-mesenchymal spectrum using a previously established quantitative scoring system. The paper also references publically available datasets and publications for hormonal receptor status, vimentin status, and molecular subtypes of these cell lines.

Key Insights and Ideas

  • EMT-specific methylation signatures: The study revealed distinct DNA methylation patterns that correlate with a cell's position on the epithelial-mesenchymal spectrum. This suggests that methylation can serve as a reliable indicator of a cell's EMT state.
  • Mesenchymal markers methylated in epithelial cells: Interestingly, genes typically expressed in mesenchymal cells (like VIM, DKK3, CRABP1) were often found to be methylated in epithelial cells. Conversely, genes characteristic of epithelial cells (GRHL2, MIR200C, CDH1) were methylated in mesenchymal cells. This "cross-methylation" highlights the complex interplay of gene regulation during EMT.
  • Potential for multi-marker panels: While some markers showed specificity, others like RASSF1A, RARß, TWIST1, and SFRP2 were methylated across both epithelial and mesenchymal cell lines. This suggests their utility in a multi-marker panel for detecting ctDNA from tumors with diverse EMT phenotypes.
  • Heterogeneous methylation is common: The study observed that heterogeneous methylation (where only a portion of DNA molecules are methylated at a specific site) is frequent, particularly in mesenchymal cell lines. This complexity needs to be considered when developing detection assays.

Key Results

  • A clear distinction in DNA methylation was observed between epithelial and mesenchymal breast cancer cell lines.
  • Mesenchymal-associated genes (VIM, DKK3, CRABP1) were frequently methylated in epithelial cell lines.
  • Epithelial-associated genes (GRHL2, MIR200C, CDH1) were primarily methylated in mesenchymal cell lines.
  • Markers like RASSF1A, RARß, TWIST1, and SFRP2 showed methylation across the epithelial-mesenchymal spectrum, making them promising candidates for broad-spectrum ctDNA detection.
  • Heterogeneous methylation was a common finding, especially in mesenchymal cell lines, and its estimation was found to be concordant between MS-HRM and pyrosequencing.

Limitations and Future Work

  • Cell line models vs. primary tumors: While cell lines are valuable models, their methylation profiles may not perfectly mirror those of primary tumors. The authors acknowledge that previous genome-wide methylation studies suggest cell line profiles largely mirror primary tumors, but further validation in clinical samples is warranted.
  • Complexity of heterogeneous methylation: Accurately quantifying heterogeneous methylation remains a challenge, although the study provides methods for estimation. Future work could focus on refining these methods for clinical application.
  • Developing a multi-marker panel: The study identifies promising markers, but the next step would be to develop and validate a multi-marker panel for robust ctDNA detection in clinical settings. This would involve assessing their performance in detecting ctDNA from patients with different stages and subtypes of breast cancer.
  • Investigating specific mesenchymally methylated markers: It remains unclear whether developing markers specifically for mesenchymally methylated cells is necessary, given that most breast tumors are predominantly epithelial. However, the contribution of mesenchymal cells to ctDNA cannot be ignored.

Summary updated

Abstract

Abstract Epithelial-mesenchymal plasticity (EMP) is a dynamic process whereby epithelial carcinoma cells reversibly acquire morphological and invasive characteristics typical of mesenchymal cells, which facilitates metastasis. Understanding the methylation differences between epithelial and mesenchymal states may assist in the identification of optimal DNA methylation biomarkers for the blood-based monitoring of cancer. Methylation-sensitive high-resolution melting (MS-HRM) was used to examine the promoter methylation status of a panel of established and novel markers in a range of breast cancer cell lines spanning the epithelial-mesenchymal spectrum. Pyrosequencing was used to validate the MS-HRM results. The results indicate an overall distinction in methylation between epithelial and mesenchymal phenotypes. The mesenchymal expression markers VIM, DKK3 and CRABP1 were methylated in the majority of epithelial breast cancer cell lines while methylation of the epithelial expression markers GRHL2, MIR200C and CDH1 was restricted to mesenchymal cell lines. We also examined EMP association of several methylation markers that have been used to assess minimal residual disease. Markers such as AKR1B1 and APC methylation proved to be selective for epithelial breast cell lines, however RASSF1A, RARß, TWIST1 and SFRP2 methylation was seen in both epithelial and mesenchymal cell lines, supporting their suitability for a multi-marker panel.
BibTeX
@misc{le2017dna,
  author = {Anh Viet-Phuong Le and Marcin Szaumkessel and Tuan Zea Tan and Jean Paul Thiery and Erik W. Thompson and Alexander Dobrovic},
  title = {{DNA methylation profiling of breast cancer cell lines along the epithelial mesenchymal spectrum - implications for the choice of circulating tumour DNA methylation markers}},
  year = {2017},
  doi = {10.1101/182600},
  howpublished = {bioRxiv},
}

Loading related content...

Figure